Santarus Inc. (SNTS) and Pharming Group (PHGUF.PK) Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
6/18/2013 9:05:46 AM
More...
|
Santarus Inc. (SNTS) President & CEO Gerald Proehl Honored as San Diego Ernst & Young LLP Entrepreneur of the Year 2013 in Life Sciences
6/17/2013 9:20:42 AM
More...
|
Santarus Inc. (SNTS) Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting
5/17/2013 7:24:07 AM
More...
|
Santarus Inc. (SNTS) Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering
5/16/2013 11:46:16 AM
More...
|
Santarus Inc. (SNTS) Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder
5/10/2013 12:43:35 PM
More...
|
Santarus Inc. (SNTS) Announces Launch of a Proposed Secondary Common Stock Offering by a Selling Stockholder
5/10/2013 10:07:37 AM
More...
|
Santarus Inc. (SNTS) Reports First Quarter 2013 Financial Results
5/7/2013 7:53:57 AM
More...
|
Santarus Inc. (SNTS) to Present at May and June Investment Conferences
5/3/2013 7:52:49 AM
More...
|
Santarus Inc. (SNTS) to Hold First Quarter 2013 Financial Results Conference Call on May 6
4/22/2013 6:30:50 AM
More...
|
Santarus Inc. (SNTS) and Pharming Group (PHGUF.PK) Announce Submission of RUCONEST Biologics License Application to FDA
4/17/2013 9:28:41 AM
More...
|
|